Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Archives

You are currently viewing the 2000 archives
Click here to return to the current data set

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: ZOCOR

« Back to Dashboard

Zocor is a drug marketed by Merck and is included in one NDA. It is available from two suppliers.

The generic ingredient in ZOCOR is simvastatin. There are thirty-six drug master file entries for this compound. Two suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the simvastatin profile page.

Summary for Tradename: ZOCOR

Patents:3
Applicants:1
NDAs:1
Suppliers: see list2

Pharmacology for Tradename: ZOCOR

Clinical Trials for: ZOCOR

A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)
Status: Terminated Condition: Type 2 Diabetes Mellitus

Clinical Trial of Zocor (Simvastatin) and Vytorin (Ezetimibe/Simvastatin) in Adolescents With Type 1 Diabetes
Status: Completed Condition: Type 1 Diabetes Mellitus; Dyslipidemia

Ezetimibe/Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133)(COMPLETED)
Status: Completed Condition: Cardiovascular Disorder; Diabetes Mellitus

Study of Metformin With Simvastatin for Men With Prostate Carcinoma
Status: Recruiting Condition: Prostate Carcinoma

Study of Heart and Renal Protection
Status: Completed Condition: Kidney Disease, Chronic

MK0524B Bioequivalence Study (0524B-070)
Status: Completed Condition: Dyslipidemia

Simvastatin With or Without Ezetimibe and Atherothrombotic Biomarker Assessment
Status: Completed Condition: Metabolic Syndrome

Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC
Status: Not yet recruiting Condition: Non Small Cell Lung Cancer

Safety of Simvastatin in LAM and TSC
Status: Recruiting Condition: Lymphangioleiomyomatosis; Tuberous Sclerosis Complex

IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)
Status: Completed Condition: Hypercholesterolemia; Myocardial Infarction

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Exclusivity Expiration
Merck
ZOCOR
simvastatin
Tablet; Oral019766Dec 23, 1991RXNoRE36481<disabled><disabled>
Merck
ZOCOR
simvastatin
Tablet; Oral019766Jul 10, 1998RXYes4,444,784<disabled><disabled>
Merck
ZOCOR
simvastatin
Tablet; Oral019766Jul 10, 1998RXYes<disabled><disabled>
Merck
ZOCOR
simvastatin
Tablet; Oral019766Dec 23, 1991RXNo<disabled><disabled>
Merck
ZOCOR
simvastatin
Tablet; Oral019766Dec 23, 1991RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc